- Patient Education
Patient Education: Elotuzumab (Empliciti) - Anti-SLAMF7 Monoclonal Antibody - Immunotherapy
Updated: Jan 27
Patient Education: Elotuzumab (Empliciti) - Anti-SLAMF7 Monoclonal Antibody - Immunotherapy
ELOTUZUMAB (EMPLICITI)
NIH National cancer institute - cancer.gov site info
This page contains brief information and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
US Brand Name(s): Empliciti
FDA Approved: Yes
MedlinePlus Information
A lay language summary of important information about this drug that may include the following:
warnings about this drug,
what this drug is used for and how it is used,
what you should tell your doctor before using this drug,
what you should know about this drug before using it,
other drugs that may interact with this drug, and
possible side effects.
Information on Empliciti website
INTERNATIONAL MYELOMA FOUNDATION:
Understanding Empliciti
IMF Understanding Series
IMF Resource Library
Current FDA-Approved Medications for Multiple Myeloma Treatment
HEALTH TREE UNIVERSITY MYELOMA:
All About Empliciti (Elotuzumab)
HealthTree University for Multiple Myeloma Lectures
Health Tree University Myeloma Videos
MULTIPLE MYELOMA RESERACH FOUNDATION:
Standard Treatments - Elotuzumab (Empliciti) - Anti-SLAMF7 Monoclonal Antibody - Immunotherapy
MMRF Education Programs
MMRF Videos
References EMPLICITI:
FDA Label Prescribing Information
Drug Label Information at DAILYMED - NIH-National Library of Medicine
Other Rsources
- Multiple Myeloma Patient Education & Information on ongoing Multiple Myeloma Clinical Trials -
* Belantamab mafodotin (Withdrawn from United States market)